Guardant Health, a company specializing in liquid biopsy tests for detecting genetic mutations, filed for provisional measures against Sophia Genetics for alleged infringement of its European patents. The patents in question relate to methods for processing genetic material, which Guardant claims are used in Sophia Genetics' MSK-ACCESS® powered with SOPHiA DDM tests.

The legal dispute involves complex genetic testing technologies and multiple patents owned by Guardant Health. The case was heard by the Paris Local Division of the Unified Patent Court (UPC), which found issues with added matter and the burden of proof for infringement. Guardant Health could not rely solely on a press release to prove infringement, needing more technical documentation to support its claims.

The court ruled on the reasonable delay for provisional measures and issues with added matter, emphasizing that the invention must be directly and unambiguously derivable from the original patent filings.